On June 16, 2026, Saudi Chemical Company Holding announced through its subsidiary AJA Pharmaceutical Industries Company the signing of a non-exclusive promotion, marketing and medical services agreement with Glaxo Saudi Arabia Limited (GSK) on June 15, 2026. The three-year agreement, with renewal opportunity, involves providing medical marketing services for GSK's pharmaceutical products in Saudi Arabia through AJA's specialized field medical teams. Financial consideration is linked to a percentage of GSK product sales in the Saudi market plus performance indicators, with annual contract value expected to be less than 5% of the Group's revenues. The agreement supports the company's strategy to expand contract sales and medical services capabilities, with positive financial impact expected to commence from the third quarter of 2026.

Original announcement:

Note: The original announcement does not explicitly specify a currency unit. Figures above are reproduced as-is. Please refer to the original announcement for details.

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.